Preparation and biological evaluation of [61Cu]bleomycin complex as a possible PET radiopharmaceutical in normal and fibrosarcoma-bearing animals

• Autorzy: Jalilian A. R. , Zandi H. , Sardari D. , Akhlaghi M. , Kamali-Dehghan M. , Shafaei K. , Majdabadi A.
• Konferencja: Proceedings of the International Conference on Recent Developments and Applications of Nuclear Technologies 15-17 September 2008, Białowieża, Poland
• Języki publikacji: EN

Abstrakty

EN

[61Cu]bleomycin ([61Cu]BLM) was prepared using [61Cu]CuCl2 produced via natZn(p,x)61Cu. [61Cu]BLM was prepared under optimized conditions (room temperature, 45 min, 0.1 mg bleomycin for 92.5–370 MBq 61CuCl2) with radiochemical purity over 98% shown by HPLC and RTLC. [61Cu]BLM was administered into normal and tumor bearing rodents up to 210 min followed by biodistribution and co-incidence imaging studies. A significant tumor/non tumor accumulation was observed either by animal sacrification or an imaging method. [61Cu]BLM can be a potential PET radiotracer for tumor imaging.

Słowa kluczowe

EN

radiopharmaceutical; copper-61; bleomycin; positron emission tomography; fibrosarcoma

• Wydawca: Institute of Nuclear Chemistry and Technology
• Czasopismo: Nukleonika
• Rocznik: 2009
• Tom: Vol. 54, No. 2
• Strony: 135--141
• Opis fizyczny: Bibliogr. 25 poz., rys.

Twórcy

autor

Jalilian A. R.

autor

Zandi H.

autor

Sardari D.

autor

Akhlaghi M.

autor

Kamali-Dehghan M.

autor

Shafaei K.

autor

Majdabadi A.

• Agricultural, Medical and Industrial Research School (AMIRS-NSTRI), Karaj, P. O. Box 31485-498, Iran, Tel./Fax: [phone],

Bibliografia

• 1. Antholine WE, Solaiman D, Saryan LA, Petering DH (1982) Studies on the chemical reactivity of copper bleomycin. J Inorg Biochem 11:75–94
• 2. Bereman RD, Winkler ME (1980) A spectral investigation of the copper complex of the antitumor compound bleomycin. J Inorg Biochem 13:95–104
• 3. Brooks RC, Carnochan P, Vollano JF et al. (1999) Metal complexes of bleomycin: evaluation [Rh-105]--bleomycin for use in targeted radiotherapy. Nucl Med Biol 26:421–430
• 4. DiGiovanni J, Rymer J, Slaga TJ, Boutwell RK (1982) Anticarcinogenic and cocarcinogenic effects of benzo[e] pyrene and dibenz[a,c]anthracene on skin tumor initiation by polycyclic hydrocarbons. Carcinogenesis 3:371–375
• 5. Fukumura T, Okada K, Szelecsényi F, Kovács Z, Suzuki K (2004) Practical production of 61Cu using natural Co target and its simple purification with a chelating resin for 61Cu-BLM. Radiochim Acta 92:209–214
• 6. Hoehn ST, Junker HD, Bunt RC, Turner CJ, Stubbe J (2001) Solution structure of Co(III)-bleomycin-OOH bound to a phosphoglycolate lesion containing oligonucleotide: implications for bleomycin-induced double-strand DNA cleavage. Biochemistry 22:5894–5905
• 7. Jaaskela-Saari HA, Kairemo KJ, Ramsay HA, Grenman R (1998) Labelling of bleomycin with Auger-emitter increases cytotoxicity in squamous-cell cancer cell lines. Int J Radiat Biol 73:565–570
• 8. Jalilian AR, Fateh B, Ghergherehchi M, Karimian A (2005) Development of [62Zn]bleomycin as a possible PET tracer. Nukleonika 50:143–148
• 9. Jalilian AR, Mirsadeghi L,Yari-Kamrani Y, Rowshanfarzad P, Kamali-Dehghan M, Sabet M (2007) Development of [64Cu]-DOTA-anti-CD20 for targeted therapy. J Radioanal Nucl Chem 274:563–568
• 10. Jalilian AR, Rowshanfarzad P, Sabet M, Novinrooz A, Raisali G (2005) Preparation of [66Ga]bleomycin complex as a possible PET radiopharmaceutical. J Radioanal Nucl Chem 264:617–621
• 11. Jalilian AR, Rowshanfarzad P, Sabet M, Shafiee A (2006) Preparation of [61Cu]-2-acetylpyridine thiosemicarbazone complex as a possible PET tracer for malignancies. Appl Radiat Isot 64:337–341
• 12. Jalilian AR, Shirazi B, Aboudzadeh R et al. (2006) [201Tl] (III)-bleomycin for tumor imaging. Radiochim Acta 94:453–459
• 13. Korppi-Tommola T, Huhmar H, Aronen HJ et al. (1999) 111In-labelled bleomycin complex for the differentiation of high- and low-grade gliomas. Nucl Med Commun 20:145–152
• 14. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ (2001) Tumor uptake of copper-diacetyl-bis(N4- methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 42:655–661
• 15. Litaka Y, Nakamura H, Nakatani T et al. (1978) Chemistry of bleomycin. XX. The X-ray structure determination of P-3A Cu(II)-complex a biosynthetic intermediate of bleomycin. J Antibiot (Tokyo) 31:1070–1072
• 16. Ma DF, Lu T, Overstreet DE, Milenic M, Brechbiel W (2002) Novel chelating agents for potential clinical applications of copper. Nucl Med Biol 29:91–105
• 17. McCarthy DW, Bass LA, Cutler PD et al. (1999) High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 26:351–358
• 18. Martindale (Rittenhouse Book Distributors) (1996) Bleomycin monograph. The Extra Pharmacopoeia, 31st ed. Vol. 1, pp 546–547
• 19. Melnyk DL, Horwitz SB, Peisach J (1987) The oxidation--reduction potential of copper-bleomycin. Inorgan Chim Acta 138:75–78
• 20. Nunn AD, Lunec J (1978) A comparison of the effect of metal-bleomycin complexes on the DNA damage and survival of cultured mammalian cells. Eur J Cancer 14:857–863
• 21. Rowshanfarzad P, Jalilian AR, Kyomarsi M et al. (2006) Production, quality control and initial imaging studies of [82mRb]Rbcl for PET studies. Nukleonika 51:209–215
• 22. Rowshanfarzad P, Sabet M, Jalilian AR, Kamali-Dehghan M (2006) An overview of copper radionuclides and production of 61Cu by proton irradiation of natZn at a medical cyclotron. Appl Radiat Isot 64:1563–1573
• 23. Stern PH, Halpern SE, Hagan PL, Howell SB, Dabbs JE, Gordon RM (1981) Cytotoxic activity, tumor accumulation and tissue distribution of ruthenium-103-labeled--bleomycin. J Nat Cancer Inst 66:807–811
• 24. Takita T, Umezawa Y, Saito SI et al. (1982) Retro-synthetic manipulation of bleomycins. Tet Lett 123:521–524
• 25. Welwyn, Herts (1973) Proceedings of 1st Int Symp on Bleomycin. London, Lundbeck Ltd